Content (24)
-
White papersClimate investing in a constrained world
How structural bottlenecks are expanding the opportunity beyond cleantech to modernize systems running the physical economy.
-
White papersWhat investors should watch as private credit market matures
Private credit entered 2026 with familiar momentum: durable investor demand, an expanding opportunity set, and a growing role in institutional portfolios. Yet the first half of the year also brought a noticeable shift in market sentiment. Headlines around redemptions from semi-liquid funds, default activity, and pockets of borrower stress have challenged the perception of private credit as a uniformly resilient and continuously expanding asset class.
-
White papersLooking beyond mega-caps
AI-focused capital flows are reshaping private markets, concentrating capital, and creating consensus exposure. We believe this dynamic has contributed to a growing divide between large-and mega-cap (predominantly) AI companies and perhaps overlooked small- and mid-cap opportunities often found in sectors outside of AI.
-
White papersPrivate credit is not a monolith
Understanding dispersion across assets, vehicles, and leverage
-
White papersThe IPO market inflection
How a new cohort of large AI-driven companies could reshape liquidity and market structure
-
White papersThe state of commercial real estate
This article draws on insights from our Commercial Real Estate Debt Advisory Group, which brings together senior Wellington investors and strategists with 300+ years of combined experience across public equity, public credit, private credit, structured credit, and macro research.
-
White papersPrivate biotech investing deep dive
Private biotech sits apart from traditional venture capital and growth equity for three key reasons. First, the potential for value creation is driven by clinical inflection points (scientific derisking) instead of revenue growth or operating scale. Second, outcomes at key readouts are often binary rather than incremental, producing wider dispersion. Finally, as private biotech companies are generally pre-revenue, they remain capital-dependent throughout their life cycle.
-
White papersThe convergence of public and private markets – a three-part full-picture perspective
Companies and issuers now operate in a capital landscape where public and private markets are continually intersecting. Across equity and debt, the traditional paradigms are breaking down, with participants more actively evaluating a range of financing options. We believe that the primary driver for this change is access to a much larger toolkit, requiring a more nuanced decision matrix. This involves weighing not only the cost of capital, but also considerations of flexibility, governance, and long-term strategic needs, among many other factors.
-
VideoPrivate Credit Roundtable (3/3): Where AI-driven infrastructure is creating credit opportunities
As AI drives demand for datacenter infrastructure, new opportunities are emerging across private credit. Our panel examines how this buildout could influence the market in the final episode of the private credit roundtable series.
-
VideoPrivate Credit Roundtable (2/3): How investors are assessing today’s credit cycle
Recent defaults have raised questions about the state of the credit cycle. In part 2 of the private credit roundtable series, our investors discuss whether these are early warning signs or simply pockets of dislocation.
-
VideoPrivate Credit Roundtable (1/3): What the return of banks means for investors
As banks begin to re-enter the market, what does it signal for private credit? In part 1 of the private credit roundtable series, our panel explores where this is happening and the potential implications for investors.
-
VideoVenture Capital Roundtable (3/3): What investors may be underestimating in 2026
What might investors be overlooking as they look ahead to 2026? From biotech shifts to climate resilience and distribution, our panel explores the themes that could shape future outcomes in part 3 of the venture capital roundtable series.
